Relatlimab
Relatlimab (BMS-986016) is a human monoclonal antibody anti-LAG-3 antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC50 value of 0.67 nM and LAG-3/FGL1 interaction with an IC50 value of 0.019 nM. Relatlimab can be used in research of cancer[1].
Product Specifications
CAS Number
1673516-98-7
Product Name Alternative
BMS-986016
UNSPSC
12352203
Target
LAG-3
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/relatlimab.html
Purity
98.00
Solubility
10 mM in DMSO
Smiles
[Relatlimab]
Molecular Weight
(145.58 kDa)
References & Citations
[1]Thudium K, et, al. Preclinical Characterization of Relatlimab, a Human LAG-3-Blocking Antibody, Alone or in Combination with Nivolumab. Cancer Immunol Res. 2022 Aug 18:CIR-22-0057.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
LY426469 100 µg
PI 3 Kinase p55 gamma (PIK3R3) (NM_001114172) Human Over-expression Lysate
Sign In for Pricing
View Details 
BNC470832-100 1x 100 µL
Calponin-1 (CNN1/832), CF647 conjugate, 0.1mg/mL
Sign In for Pricing
View Details